AI-generated summary
The authors compared split-face treatment of melasma over 12 weeks, with one side receiving intradermal tranexamic acid plus low fluence Q-switched Nd:YAG laser and the other side receiving tranexamic acid injection alone. They report a statistically significant greater decrease in mMASI scores on the combination side at 12 and 24 weeks, with minimal side effects. Limits stated include a single-sex sample of 40 patients aged 35 to 45.
- Participants
- 40
- Who or what was studied
- 40 female patients aged 35-45 years with melasma
- Limits stated in the abstract
- The abstract describes a split-face study of 40 female patients aged 35-45 years, so findings may not generalize to other ages, sexes or populations.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.